Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Press Release Funding the Future of Cancer Research Cancer Research Heroes Improving Conventional Wisdom: From CAR-T Therapy to Diversity in STEM, Avery Posey Has Big Ideas Press Release Ute Dugan Joins PICI as Senior VP of Clinical Research Partner Highlight Seeking Solutions for Deadly Brain Tumors: ACGT Our Impact, Research Update Tackling Pancreatic Cancer with a Triple Threat Our Impact Highlights of 2020: PICI’s Progress
Cancer Research Heroes Improving Conventional Wisdom: From CAR-T Therapy to Diversity in STEM, Avery Posey Has Big Ideas